HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment.

Abstract
We assessed the intraluminal pH and mucosal prostaglandin E2 (PGE2) concentrations in patients (nonresponders) whose gastric ulcer did not heal after an initial 2 months and subsequent 3 months of treatment with one of five H2-receptor antagonists (H2RAs). The efficacy of misoprostol, a PGE1 analogue, or AG-1749, a proton-pump inhibitor, on ulcer healing in nonresponders was also tested. The percentage of time (24-h measurement) during which the pH was 3 or more was higher in the basal condition (no H2RA) in nonresponders than in good responders with healing in the first 2 months. H2RAs increased this percentage satisfactorily in nonresponders as well as in good responders. The mean mucosal PGE2 concentration in the ulcer rim was 26 ng/g of tissue in nonresponders, much lower than in good responders. Treatment with misoprostol combined with an H2RA resulted in 60% success for ulcer healing within the next 2 months in nonresponders, without affecting the intraluminal pH measured during treatment with an H2RA alone. AG-1749 raised the percentage of time with high pH to 99% from the 68% obtained with an H2RA and cured 88% of this type of ulcer. These results suggest that extremely low PGE2 levels in gastric mucosa are related to the effectiveness of the H2RA. In such a condition, the small amount of gastric acid that is still secreted even during treatment with an H2RA may interrupt ulcer healing. Therefore, treatment with a prostaglandin analogue combined with an H2RA or treatment with a proton-pump inhibitor may be useful for ulcer healing in nonresponders.
AuthorsT Arakawa, K Higuchi, T Fukuda, H Nakamura, K Kobayashi
JournalJournal of clinical gastroenterology (J Clin Gastroenterol) Vol. 13 Suppl 1 Pg. S129-33 ( 1991) ISSN: 0192-0790 [Print] UNITED STATES
PMID1682356 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Histamine H2 Antagonists
  • Misoprostol
  • Lansoprazole
  • Dinoprostone
  • Omeprazole
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents (therapeutic use)
  • Dinoprostone (metabolism)
  • Female
  • Gastric Mucosa (metabolism)
  • Histamine H2 Antagonists (therapeutic use)
  • Humans
  • Hydrogen-Ion Concentration
  • Lansoprazole
  • Male
  • Middle Aged
  • Misoprostol (therapeutic use)
  • Omeprazole (analogs & derivatives, therapeutic use)
  • Peptic Ulcer (drug therapy, physiopathology)
  • Wound Healing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: